Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Rad LaboratoriesFRA:BUWA +1.43%70 EV-to-EBITDA is 16.55 as of Aug. 13, 2026, which is 273% above its 10-year median of 4.44. GuruFocus rates FRA:BUWA with a GF Score™ of 70/100 and a GF Value™ of €276.56 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 514 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks worse than 55.25% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bio-Rad Laboratories's enterprise value is €8,062 Mil.
Bio-Rad Laboratories's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €487 Mil. Therefore, Bio-Rad Laboratories's EV-to-EBITDA for today is 16.55.
The historical rank and industry rank for Bio-Rad Laboratories's EV-to-EBITDA or its related term are showing as below:
FRA:BUWA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -237.71 Med: 4.44 Max: 1734.77
Current: 16.39
During the past 13 years, the highest EV-to-EBITDA of Bio-Rad Laboratories was 1734.77. The lowest was -237.71. And the median was 4.44.
FRA:BUWA's EV-to-EBITDA is ranked worse than 55.25% of 514
companies
in the Medical Devices & Instruments industry
Industry Median: 14.825
vs FRA:BUWA: 16.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio-Rad Laboratories's PE Ratio (TTM) for today is calculated as:
Bio-Rad Laboratories's share price for today is €312.20.
Bio-Rad Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.050.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bio-Rad Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BUWA vs GKOS, BRKR, GMED: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's EV-to-EBITDA falls into.
Bio-Rad Laboratories's current Enterprise Value is €8,062 Mil.
Bio-Rad Laboratories's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €487 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (FRA:BUWA) has a EV-to-EBITDA of 16.55 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bio-Rad Laboratories. This is 273% above median its historical median of 4.44. According to the industry distribution chart, Bio-Rad Laboratories ranks #284 out of 514 companies in the Medical Devices & Instruments industry, placing it in the top 55.3%.
Is Bio-Rad Laboratories' EV-to-EBITDA too high?
Bio-Rad Laboratories' current EV-to-EBITDA of 16.55 is 273% above median its 10-year median of 4.44. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.83. Bio-Rad Laboratories' value of 16.55 is 11.6% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #284 out of 514 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' EV-to-EBITDA compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #284 out of 514 companies for EV-to-EBITDA. This places Bio-Rad Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 14.83. Bio-Rad Laboratories' value of 16.55 is 11.6% above this benchmark. While the company's 10-year median is 4.44 vs. the industry median of 14.83, Bio-Rad Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.83, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current EV-to-EBITDA of 16.55 is 11.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bio-Rad Laboratories. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current EV-to-EBITDA is 16.55, which is 273% above median its own 10-year median of 4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Modestly Overvalued. The stock's GF Value™ is €276.56, compared to a current price of €312.20 — trading 12.9% above its estimated fair value. The current EV-to-EBITDA is 16.55, which is 273% above median its 10-year median of 4.44 and 11.6% above the Medical Devices & Instruments industry median of 14.83. Bio-Rad Laboratories' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current EV-to-EBITDA is 16.55 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be overvalued.
The current stock price of €312.20 is trading 12.9% above its estimated GF Value™ of €276.56.
GuruFocus considers Bio-Rad Laboratories to be Modestly Overvalued.
Key valuation signals for FRA:BUWA:
EV-to-EBITDA: 16.55 (273% above median its 10-year median of 4.44)
GF Value™: €276.56 vs. price of €312.20 (12.9% above fair value)
Industry Position: 11.6% above the Medical Devices & Instruments median (#284 of 514)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
70GF Score
Get the complete analysis for FRA:BUWA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
